준영메디칼

비상장계속사업자

JUNYOUNG MEDICAL

이준호

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

준영메디칼

Business Reg. No. 2148617763 · CEO 이준호

I.Investment Overview

Target준영메디칼 (2148617763)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명준영메디칼
영문명JUNYOUNG MEDICAL
대표자이준호
사업자등록번호2148617763
법인등록번호1101111441883
설립일1997.08.05
종업원수17명

V.Workforce

17

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW145.52021148.12022161.720231722024165.22025
영업이익100M KRW-51.42021-6.320221.620238.520243.92025
순이익100M KRW-82.42021-5.620220.82023320246.52025
Item20252024202320222021
자산총계145.1억원151.3억원145.3억원135.9억원160.7억원
부채총계51.1억원63.8억원60.8억원52.3억원71.4억원
자본총계94억원87.5억원84.5억원83.7억원89.3억원
매출액165.2억원172억원161.7억원148.1억원145.5억원
영업이익3.9억원8.5억원1.6억원-6.3억원-51.4억원
순이익6.5억원3억원7,960만원-5.6억원-82.4억원

VII.Financial Ratios

FY2025 basis

2.34%

영업이익률

3.93%

순이익률

4.47%

ROA

6.9%

ROE

54.36%

부채비율

64.79%

자기자본비율

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

준영메디칼 투심보고서 | Alpha Lenz